Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 38.55 USD -0.67%
Market Cap: 22.3B USD

Operating Margin
Royalty Pharma PLC

65.2%
Current
50%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
65.2%
=
Operating Profit
1.5B
/
Revenue
2.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Royalty Pharma PLC
NASDAQ:RPRX
22.4B USD
65%
US
Eli Lilly and Co
NYSE:LLY
957.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
506.9B USD
27%
CH
Roche Holding AG
SIX:ROG
251.8B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
207.6B GBP
24%
CH
Novartis AG
SIX:NOVN
202.5B CHF
33%
US
Merck & Co Inc
NYSE:MRK
248.2B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
206B USD
11%
US
Pfizer Inc
NYSE:PFE
146.9B USD
29%
No Stocks Found

Royalty Pharma PLC
Glance View

Royalty Pharma PLC operates within a unique niche of the pharmaceutical industry, using a business model that might seem more akin to financial engineering than traditional drug development. Founded by Pablo Legorreta in 1996, the company has carved out a role as a specialized investment entity, acquiring pharmaceutical royalties from innovative biopharmaceutical companies. Essentially, Royalty Pharma provides capital to these firms upfront or participates in funding their development projects, and in return, it earns a slice of the future sales of the companies' drugs. This strategy makes Royalty Pharma a distinct player that benefits indirectly from the pharmaceutical market's successes while largely sidestepping the substantial risks associated with drug development. The company thrives on a diversified portfolio of royalties spanning numerous therapeutic areas, including rare diseases, oncology, and neurology, among others. This diversification mitigates risk and offers a stable cash flow pattern, as the success of one drug can offset challenges faced by another. Notably, Royalty Pharma’s earnings are impacted by the performance of highly successful drugs like Vertex’s cystic fibrosis therapies and Janssen’s cancer drug Imbruvica. By tapping into the promising prospects of life-saving and high-demand pharmaceutical innovations, it has created a profitable loop of continuous royalty accrual, translating clinical triumphs into financial well-being. Through this model, Royalty Pharma positions itself as a kingmaker, enabling biopharma to reach groundbreaking milestones while collecting revenue as these therapies transform the healthcare landscape.

RPRX Intrinsic Value
64.82 USD
Undervaluation 41%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
65.2%
=
Operating Profit
1.5B
/
Revenue
2.3B
What is the Operating Margin of Royalty Pharma PLC?

Based on Royalty Pharma PLC's most recent financial statements, the company has Operating Margin of 65.2%.

Back to Top